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Role of IL-6 in Uremia-Induced 
Muscle Dysfunction
Taylor Penzel, Maria P. Martinez-Cantarin, MD*,
(*) indicates primary project advisor
Introduction
Uremia associated with chronic kidney disease (CKD) 
results in skeletal muscle atrophy, progressive muscle 
weakness and premature muscle fatigue, and muscle 
wasting is an independent predictor of mortality in CKD 
patients. 
• Significant contributors to muscular dysfunction
– Defects in mitochondrial function 
– High circulating levels of inflammatory cytokines such as 
IL-6 and TNF-α
• Further research is necessary to elucidate the specific 
roles of IL-6 and TNF-α in these processes.
Introduction
Objective: To determine the phenotype of uremic skeletal muscle 
in a mouse model of advanced kidney disease and assess the 
contribution of IL-6 to the muscle dysfunction.
Clarifying the pathophysiology of 
inflammatory damage to muscles may 
contribute to the identification of 
therapeutic targets to that can improve 
mortality, functional capacity and 
quality of life for patients with CKD.
Fig 1: Intersection of aging, CKD 





– What effect does uremia have on muscular and mitochondrial structure 
and function in uremic WT mice compared to controls?
– Can abrogation of IL-6 attenuate muscular and mitochondrial damage in 
uremic IL-6 knockout mice compared to uremic WT mice?
• Hypotheses
– Uremic mice will present with muscle atrophy and fiber type switching 
from a more oxidative to a more glycolytic phenotype compared to 
control mice. 
– Uremic mice will present with mitochondrial dysfunction and a decrease 
in mitochondrial mass compared to control mice. 
– Abrogation of IL-6 will attenuate uremia-induced changes in skeletal 
muscle and mitochondrial structure and function.
Approach & Results
• Study design: Descriptive study of an animal model of advanced kidney disease
• Population / study sample: WT mice and IL-6 KO mice
• Intervention: Adenine supplementation of the mouse diet in order to develop advanced 
kidney disease




› Overall weight and muscle 
weights
› Fiber number per field 
(histopathology analysis)
› Fiber diameter 
(histopathology analysis)




activated receptor γ 
coactivator 1α (PGC1α, 
positive regulator of 
mitochondrial biogenesis and 
function; mRNA expression)
› Quantification of 
mitochondrial complexes (I-
V) (optical density)
• Data source and collection: Muscle tissue of the different mice cohorts
• Analysis: General descriptive statistics
Fig. 2: Immunofluorescence stain of muscle fiber types in 











































As expected, WT mice on  0.2% 
adenine diet had higher BUN, 
lower overall weight, and lower 
individual muscle weights than 
controls. 
The EDLs of WT control mice 
had a significantly higher 
number of larger diameter 































































The EDLs of IL6KO control 
mice had no significant 
difference in fiber diameter 




















































































WT control CKD mice 
had significantly 
decreased optical 
density of complexes I-
V in gastrocnemius 
mitochondria.
There was no 
significant difference in 
the optical density of 
complexes I-V in 
gastrocnemius 
mitochondria of IL6KO 




































Compared to controls, WT CKD mice 
had significantly reduced 
gastrocnemius expression of PGC1α.
However, IL6KO mice had no significant 
difference in gastrocnemius expression 
of PGC1α between study groups.
Conclusions
• In line with previous research, WT mice with induced CKD had:
– Reduced muscle weights
– Significant changes in size of EDL fibers across all fiber types, 
– Decreased optical density of complexes I-V in gastrocnemius mitochondria
– Reduced gastrocnemius expression of PGC1α when compared to controls.
• Uremic IL6KO mice did show reduced body and individual muscle 
weights compared to controls, but showed no significant changes in:
– Size of EDL fibers by type
– Optical density of complexes I-V in gastrocnemius mitochondria
– Gastrocnemius expression of PGC1α 
• These data indicate that IL-6 directly disrupts mitochondrial function 
and demonstrate specific mitochondrial targets of its action. IL-6 may 
be an important therapeutic target to improve quality of life and 
mortality in CKD patients.
Future Directions
• This project is ongoing. We plan to:
– Continue immunofluorescence analysis of muscle 
fiber type beyond EDL in IL6KO mice
– Include a cohort of TNF-α KO mice 
• If strong evidence ultimately emerges to 
implicate IL-6 or TNF-α in uremia-induced 
muscle damage, trials with existing 
monoclonal antibody therapy may become a 
possibility
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